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Oral or intragastric administration of antigens such as foreign proteins or
erythrocytes is known to cause the appearance of circulating antibodies which
frequently are predominantlyofthe IgAclass (1). Some ofthis antibody is made
locally in the immunized gut wall (2, 3), but an additional, as yet unspecified,
fraction originates in extraintestinal lymphoid tissues, particularly the spleen.
In thisorgan, many PFC, chieflyoftheIgAclass, canbe identified 1 wk after a4
day course of intragastric immunization with sheep red blood cells (SRBC) (4).
Reasons for attributing this preference for IgA to the colonization ofthe spleen
and lymph nodes by IgA-committed cells triggered by antigen in the gut wall
have been set forth in recent reviews (1, 5).
While exploring the immunologic memory of this type of immune response,
we encountered a second striking feature of the systemic effects of enteric
(mucosal?) immunization. When our standard 4-day intragastric SRBC course
given to mice was repeated 2-3 wk after a similar primingcourse, i.e. at atime
when the primary spleen response had subsided, the expected booster effect was
not obtained; it was in fact replaced by a complete absence of response, and it
took several months for systemic reactivity to renewedintragastric challenge to
be restored to the level of an ordinary primary response (4). We termed this
phenomenon "negative immunologic memory" (5).
The relevance of these intriguing findings with respect to work on oral
vaccination need not be pointed out. It was therefore clearly important to gain
insight into its mechanism, with the hope that this *ould suggest means of
avoiding or manipulating the phenomenon at will.
In our previous work, hyporesponsiveness had been assessed by giving the
challenging dose ofantigen intragastrically. Therefore thepossibility remained
that coproantibody induced by the primary immunization had interfered with
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the absorption ofthe challenging antigen. We have in fact established its ability
to do so (6). In the present studywe will, however, demonstrate that intragastric
immunization also caused hyporesponsiveness to parenteral challenge, andthat
one is therefore dealing with a genuine form of tolerance. It will also be shown
that a tolerogenic factor present in the serum of intragastrically immunized
animals and presumably consisting of immune complexes with IgA as the




Conventional BALB/c/Cen mice ofboth sexes, raised at the laboratory, were used at




SRBC and horse red blood cells (HRBC' were obtained from the Institut Pasteur,
Paris, France, and were washed three times with phosphate-buffer saline before use.
Immunization and Challenge Schedules
INTRAGASTRIC IMMUNIZATION OR CHALLENGE. Intragastric immunization or challenge was
performed by giving mice 4 x 109 SRBC by intragastric intubation after 8 h of fasting, the
procedure being repeated on 4 consecutive days.
PARENTERAL IMMUNIZATION OR CHALLENGE.
￿
Parenteral immunization or challenge consisted
of a single-intraperitoneal (i .p.) injection of 2 x 109 SRBC (in some cases HRBC.
Antimouse Sera.
￿
Rabbit antisera specific for mouse IgA and IgG (without subclass distinc-




Carotid blood from ether-anesthetized mice was allowed to clot at
room temperature and the serum was inactivated at 56°C for 30 min. Mouse anti-SRBC antibodies
of IgM nature were hemolytic and could therefore be titrated directly, whereas indirect hemolysis
by added antimouse IgA or antimouse IgG had to be employed for anti-SRBC of the other Ig
classes. A microtitration apparatus was used (Microtiter, Cooke Laboratory Products Div., Dyna-
tech Laboratories Inc., Alexandria, Va.).
Plaque-Forming Cell (PFC) Assays.
￿
PFC were enumerated after mixing SRBC or HRBC with
spleen cells according to a previously described modification (4) of the fluid-medium procedure.
The final mixtures contained 0.1 ml of spleen cells and 0.9 ml of a SRBC or HRBC suspension of
appropriate concentration. This system was convenient for the enumeration of direct PFC as-
sumed to produce IgM antibodies. For the assay of IgA or IgG PFC, antiserum specific for mouse
IgA or IgG was added in optimal amounts, and the net numbers of IgA or IgG PFC were computed
from the difference between counts on these "indirect" slides and those from the "direct" slides
with no added antiserum .
PFC Inhibition Assays.
￿
Serum from normal or immunized mice was tested for inhibitory
activity towards PFC from i.p. immunized mice by incubating 25 x 10, spleen cells for 30 min at
37°C with 0.5 ml of the serum to be assayed or, for the control, with 0.5 ml of Eagle's medium
containing 20% fetal calf serum (FCS). The cells were then centrifuged at 200g for 5 min at room
temperature and resuspended in 0.5 ml of Eagle's medium plus 20% FCS, after which they were
plated in the usual manner for the incubation. The viability ofthe spleen cells, as assessed by the
trypan blue exclusion test, was about 95%.
Detection and Removal of Circulating Antigen-Antibody (AgAb) Complexes.
￿
The presence of
AgAb complexes in the serum from mice immunized with SRBC or in normal control sera was
detected, and their concentration semiquantitatively assessed, by two tests based on the ability of
such complexes to inhibit the agglutination of polystyrene ("latex") particles coated with human
IgG by rabbit rheumatoid factor (RF) orthe Clq component ofrabbit complement (C), respectively.
I Abbreviations used in this paper: AgAb, antigen-antibody; BSA, bovine serum albumin; FCS,
fetal calfserum; HRBC, horse red blood cells; HSA, human serum albumin; PFC, plaque-forming




















* Averages ofcounts from the spleens of the number ofanimals indicated.
t 1.6 x 10'° SRBC divided over four daily doses of 4 x 10' SRBC.
§ Single IP dose of 2 x log SRBC.
11 No IgA or IgG PFC were found.
9 ND, not done.
Further details on this technique will be given in a forthcoming publication.' Soluble AgAb
complexes were eliminated by absorbing the serum on Sepharose-bound rabbit rheumatoid factor
according to a method to be described elsewhere.3
Results
Effect ofIntragastric Preimmunization on the Response to Parenterally Ad-
ministeredAntigen. The response ofmice givena single i.p. injectionof2 x 108
SRBC is shown in Table I.
In control animals (group 1), i.e. without previous contact with the antigen,
the splenic PFC response was virtually all ofthe IgM class and peaked at day 4
with 256PFC/106spleen cells. Animalshaving received fourintragastric doses of
4 x 109 SRBC each, on days -14 through -11 before the i.p. injection of2 x 108
SRBC (group 2A) likewise showed asplenic PFC response oftheIgMclasswith a
maximum at day 4, but the magnitude ofthis response was eight times smaller
than in the control group. If a similar 4-day intragastric preimmunization
course was given three months before the i.p. injection of 2 x 108 SRBC (group
2B), the response resembledthat seen in the controls, although thePFC peak on
day 4 still averaged only 162 PFC/106 spleen cells. Group 3 is added as a control
to showthat parenteral priming with a comparable total dose ofantigen set the
stage for a vigorous secondary response. No hemolytic antibody activity,
' Lurhuma, A., C. L. Cambiaso, P. L. Masson, and J. F. Heremans. 1975. Detection ofcirculat-
ing antigen-antibody complexes by their inhibitory effect on the agglutination of IgG-coated
particles by rheumatoid factor or Clq. Manuscript submitted for publication.
9 Cambiaso, C. L., P. L. Masson, and J. F. Heremans. The use of insolubilized rheumatoid
factor and Clq for isolating immune complexes. Manuscript in preparation.
per test . . . . . . . . . . . . 5 5 3 3
days after
single i.p . dose IgMPFCl10g IgMPFC1106 IgMPFC110° PFCIIOgspleen cells
of2 x 10" spleen cells 11 spleen cells 11 spleen cells11 IgM IgA IgG SRBC
0 1 3 1 ND1f ND ND
2 17 1 9 68 50 135
4 256 32 162 ND ND ND
5 94 9 53 ND ND ND
6 69 1 30 ND ND ND
7 62 1 ND 30 27 157
11 35 2 14 ND ND ND




Effect of Intraperitoneal Priming on the Spleen PFC Response* to a 4 day Intragastric
Immunization with SRBC
No previous priming, group 4
￿
i.p . priming 2 wk before$, group 5
* Averages of counts from the spleens of the number of animals indicated .
f Single IP dose of 2 x 108 SRBC .
§ 1 .6 x 10'9 SRBC divided over 4 daily doses of 4 x 109 SRBC .
whether direct (IgM) or indirect (IgG or IgA), could be detected in the serum of
nonimmunized mice . In five animals ofgroup 1, direct (IgM) hemolytic activity
was found at titers of 1/4,096, 1/2,048, 1/2,048, 1/512, and 1/256, respectively, on
day 4 . In five animals ofGroup 2A, the IgM antibody titers found on day 4were,
respectively, 1/128, 1/128, 1/64, 1/32, and 1/16, in agreement with the depression
of their IgM PFC counts .
Effect of Parenteral Preimmunization on the Response to Intragastrically
Administered Antigen . The splenic PFC response of mice given a 4 day course
of intragastric immunization with 4 x 108SRBC as the daily dose is shown in
Table II .
The control series (group 4) having experienced no previous contact with the
antigen, is taken from a previous publication (4) . In these animals the splenic
PFC response extended over all three immunoglobulin classesbutpredominated
in the IgA class and reached a maximum on day 9.
Parenteral preimmunization with a single i.p . dose of 2 x 101, SRBC on day
-14 before the onset of the intragastric course (group 5) significantly changed
this pattern of response in only one respect, namelyby raising the starting base-
line level ofIgM PFC, from virtually none, to 25 PFC/106 spleen cells. This was
obviously a carry-over from the primary response to the i.p . injection of antigen,
since IgMPFC again declined to half thatnumber within 1wk . Forthe rest, the
response was predominantly IgA and peaked at day 9, exactly as in the control
group .
Tolerogenic Effect In Vivo ofSerum from Mice Intragastrically Immunized
with SRBC . Mice were giventhe standard course of four intragastric doses of 4
x 108SRBC at daily intervals, and their serum was collected on day 14 afterthe
first dose . These sera exhibited neither direct IgM nor indirect IgG hemolytic
activity, but contained IgA anti-SRBC antibodies at titers ranging from 1/1 to













0 1 0 0 25 0 0
6 3 1 0 13 2 0
8 22 25 3 13 23 7
9 23 55 11 15 56 13
10 17 18 4 9 14 3
13 4 4 0 2 3 0




Effect ofIP Injection of Serumfrom Intragastrically ImmunizedMice Upon theSubsequent
Splenic PFC Response to Intragastric SRBC Antigen*
* Tested on day 9 after the first offour intragastric doses of 4 x 1(lo SRBC, i.e., at the peak ofthis type ofresponse.
t 0.5 ml of pooled immune serum given 8 h before the first intragastric dose.
§ -, no detectable hemolytic activity.
1/8, and demonstrable by the indirect hemolysis assay. These sera were pooled
and the IgA anti-SRBC titer was adjusted to 1/2 by appropriate dilution with
normal mouse serum.
When 0.5 ml of this immune serum from enterically stimulated mice was
injected intraperitoneally to recipient mice 8 h before the onset of a 4 day
intragastric course with 1.6 x 1010 SRBC (group 7, Table III) or 8 h before a
single i.p. injectionof2 x 108 SRBC (group 9A, TableIV), thesubsequent splenic
PFC responses and serum antibody titers after both types of antigenic stimula-
tion were considerably depressed. In these experiments, the controls were mice
similarly treated with antigen but having received no i.p. pretreatment with
immune serum (group 6, Table III; and group 8, Table IV). In both cases the
recipients' responses were assessed at the time they should normally have
reached their maximum, viz. on day 9 for the intragastric group andon day4for
the i.p. group.
When the whole antigenic load of 1.6 x 1010 SRBC was given to the serum
donors in a single intragastric dose instead ofbeing divided over four consecu-
tive days, and their serum was collected within 1 day instead of 2 wk later, no
tolerogenic effects were obtained by injecting it i.p. to recipients challenged i.p.
8 h later (group 913, Table IV). The pooled serum used in this experiment
possessed neither direct IgM nor indirect IgG or IgA hemolytic activity.
Tolerogenic Effect In Vitro ofSerum from Mice Intragastrically Immunized
with SRBC. The report by Schrader and Nossal (7) on the capacity of tolero-
genic material to block the activity of PFC in vitro prompted us to verify
whether similar inhibiting activity would be displayed by the tolerogen which
the preceding invivoexperimentshad showntoexistinthe serumofintragastri-
cally immunized mice.
For this purpose mice were given an i.p. priming with 2 x 108 SRBC together
with 2 x 108 HRBC, and their spleens were tested for direct PFC of both
specificities, 4 days after the injection. The spleen cells were exposed for 30 min
to various media before being washed and plated for the Jerne plaque assay, as
Animal no. Not pretreated (controls), group 6
One i.p. injection# of serum from mice
intragastrically immunized with four
doses of4 x 10' SRBC 2 wk before,
group 7
PFC1106 Serum antibody PFC1106 Serum antibody
spleen cells reciprocal titers spleen cells reciprocal titers
IgM IgA IgM IgA IgM IgA IgM IgA
1 21 53 - 4 0 2 - -
2 12 60 - 8 0 1 - 2
3 17 28 - 4 0 0 - -
4 5 60 - 4 0 2 - 1
5 16 33 - 8 0 2 - 1




Effect of i.p. Injection of Serumfrom Intragastrically Immunized Mice Upon the Subsequent
SplenicPFC Response to Intraperitoneal SRBC Antigen`
` Tested on day4 after the i.p. dose of 2 x 1(la SRBC, i.e., at the peak of this type of response.
$ 0.5 ml of serum given 8 hbefore the i.p. dose.
§ Same immune serum as given to group 7, Table III.
describedunderMaterials andMethods. The results (exp. 1, Table V) show that,
with reference to the control using Eagle's medium enriched with FCS, normal
mouse serum had no blocking effect whatever. In contrast, marked inhibition of
anti-SRBC but not of anti-HRBC PFC activity occurred when the cells hadbeen
exposedto serumfrom mice intragastrically immunizedwith SRBC 2 wk before.
Also in analogy with the in vivo findings, this blocking activity was absent from
serum collected 1 day after the total immunizing dose (1.6 x 101° SRBC) was
given as a single intragastric dose.
As mentioned in describing the in vivo tolerization experiments, the serum
pool from animals immunized intragastrically 2 wk before containéd IgA anti-
bodies to SRBC. No direct test wasavailable to assaythis blocking serum forthe
simultaneous presence of antigen, but it was thought that, by that time,
circulating SRBC material might at best persist only in trace amounts and
would therefore occur in combination with antibody. The assay for immune
complexes (cf. Materials and Methods) proved negative when Clq was used as
the reagent, but was positive at a 1/8 dilution with RF. A serum pool from non-
immunized mice was also negative with Clq, whereas its inhibition titer with
RF was 1/2. When the blocking serum was absorbed with insolubilized RF (cf.
Materials and Methods), its inhibition titer with RF dropped to the control value
of 1/2. This absorbed serum was then tested againfor in vitro inhibitory activity
towards direct PFC elicited by i.p. immunization. As shown in the lower part of
Table V, all such activity was abolished by the removal of material retained by
RF .
Discussion
Systemic Unresponsiveness after Immunization by the Digestive Route is not
due to Impaired Absorption of Antigen Caused by Coproantibody, but is a
Genuine Form of Tolerance. Reports from different laboratories (6, 8, 9) indi-
cate that immunization by the digestive route leads to impaired enteric absorp-
Animal no. Not pretreated (controls), 8
One i.p. injection$ of serum from mice having
received intragastrically:
group
4doses of 4 x 10° SRBC 1 dose of 1.6 x 10'° SRBC
2 wk before, group 9A§ 1 daybefore, group 9B
IgMserum IgMserum IgMserum
IgMPFC110° antibody IgMPFC110° antibody IgMPFC1101 antibody
spleen cells reciprocal spleen cells reciprocal spleen cells reciprocal
titers titers titers
1 102 256 5 4 180 1,024
2 200 512 0 2 190 256
3 562 4,096 0 2 310 256
4 170 1,024 0 2 250 512
5 170 2,048 3 2 150 256
Mean - SD 240.8 - 183.1 1,587 - 1,561 1.6 - 2.9 2.5 - 0.9 246.0 - 63.9 461 - 334ANDR19, HEREMANS, VAERMAN, AND CAMBIASO
TABLE V
Specific Paralyzing Effect In Vitro ofSerumfrom Intragastrically Immunized Mice
Upon Splenic PFC from Parenterally Primed Animals, and Removal of the Inhibitory
Material by Absorption with Rheumatoid Factor
* Mean ± SD from 7.
f Mean ± SD from 3 .
§ 1 .6 x 10'8 SRBC divided over four doses of 4 x 108 SRBC .
111.6 x 10'8 SRBC in a single dose .
Direct PFC/108 spleen cells on day 4
after one i.p . priming with 2 x 108 SRBC
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tion of macromolecular antigens . More specifically we have been able to show
that in rats having received a single dose of 200 mg of human serum albumin
(HSA) by gastric intubation, the capacity ofthe gut to transfer intact albumin
molecules from the gut contents into the blood was decreased to less that 50% of
its normal level by the 2ndwk after the immunization, and that secretory IgA
coproantibody, presentin the enteric lumenat that time, was responsible for the
effect (6).
A priori, therefore, impaired uptake of antigen might have been a factor in
the previously reported hyporesponsiveness to SRBC caused by intragastric
immunizationandrevealedupon rechallengeby the digestiveroute (4) . Here we
show, however, that similar unresponsiveness is found when the enteric portal
ofentry is bypassed by injecting the challenging dose ofantigen i .p . (group 2A,
Table I) . One is therefore dealing with tolerance, not with lack of uptake of
antigen .
The slowness of recovery, as revealed by parenteral challenge after 3 mo
(group 2B, Table 1), has also been notedformerly when the challenge was given
intragastrically (4), and is of relevance to the discussion of the mechanisms
involved (see below) .
At any rate, powerful tolerizing capacity seems to be one of the features
inherent to the enteric (mucosal?) mode of administration of antigen. It is
therefore surprising that the literature should so rarely have alluded to this
phenomenon . It is not clear to what extent it is related to the still unexplained
"Sulzberger-Chase phenomenon" (10), by which systemic toleranceis induced in
guinea pigs by feeding them chemically active haptens capable of conjugation




mean ± SD mean ± SD
Exp . 1
Eagle's + 20% FCS 180 ± 47 238 ± 119
Normal mouse serum 190 ± 10 227 ± 114
2-wk postgastric immunization serum§ 32 ± 8 224 ± 117
1-day postgastric immunization serum ~~ 182 ± 29 ND
Exp . 2
Eagle's + 20% FCS 225 ± 68




with bodycomponents or foreignhelper antigens from the gut contents. Abetter
parallel exists with the recent report by Thomas and Parrott (1), that systemic
hyporesponsiveness to bovine serum albumin (BSA) is found in rats after 2 wk of
daily intragastric administration of25 mg of this antigen (see below).
Parenteral Priming, in Contrast to Intragastric Priming, Appears to have
Little Effect on the Systemic Response to Subsequent Intragastric Chal-
lenge. Besides its predominant IgA character and its propensity to cause
subsequent unresponsiveness, the immune response to intragastric administra-
tion ofantigendisplays yeta third unusual feature, which is evidentfrom Table
II.
Parenteral priming with an immunogenic doseofSRBC is ofcourse aclassical
means to prepare a mouse for a vigorous secondary response to a second
immunogenic dose ofthe same antigen, given parenterally 2 wk later (group 3,
Table I). Yet, when challenged by the enteric route (group 2, Table II), the
parenterally primed animals behaved as if they had never before encountered
the antigen. Except for the understandable carry-over of some IgM PFC from
the primary response, their "secondary" response was in all points similar to a
primary enterically induced reaction.
A rational explanation is however available if one accepts our previous
proposal that splenic PFC responses after enteric administration ofantigen are
not due to resident cells ofthespleen but to immigrants from the stimulated gut
wall. Reports on the enteric absorption ofHSA in rats (6) and BSA in rats (11)
agree that less than 0.1% of an intragastric dose of these antigens reaches the
circulation as intact macromolecules. Intragastric challenge is therefore proba-
bly insufficient to reveal immunologic memory in spleen cells primed by the
parenteral route. Then, any response observed in that organ must reflect the
reaction of immigrant cells to contact with antigen in the gut wall. Now,
parenteral priming has been shown only minimally to affect the lamina propria
of the bowel (12), which is probably neither primed nor tolerized by such a
preparation. It is only logical, then, that the "secondary" spleen response to
intragastric antigen after parenteral priming, should assume the features ofa
primary enterically induced reaction .
Tolerance Induced by Intragastric Immunization is Mediated by a Circulat-
ing Tolerogen Presumably Consisting ofImmune Complexes Containing IgA
Antibody . Our data clearly indicate that the specific hyporesponsiveness
shown by mice 2 wk after intragastric immunization with SRBC can be trans-
ferred passively to virgin recipients by means ofserum. This circulating tolero-
gen has a powerful blocking effect on parenteral (Table IV) as well as enteric
(Table III) challenges.
Some idea as to the mode ofaction ofthe tolerogen is affordedby the fact that
it paralyses, in vitro, the activity of B cells already engaged in antibody
production and secretion (Table V). This does not exclude the existence ofother,
perhaps more important, targets for its action. One would envisage in the first
place the possibility of an inhibitory effect on the primary triggering of the B
cell; experiments now in progress aim at elucidating this point.
The in vitro effect of the enterically induced tolerogen on pre-existing PFC is
evidently analogous tothe phenomenon described by Schrader and Nossal (7) asANDRE, HEREMANS, VAERMAN, AND CAMBIASO
￿
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"effector cell blockade." In their experiments the paralyzing agent was highly
multivalent antigen such asdinitrophenylated flagellin, whereas in the present
case the relationship between the inducing enterically given antigen (SRBC)
and the resultingcirculating tolerogenis notimmediately apparent. The follow-
ing reasoning may clarify this question.
In theirstudyon orally induced tolerance to BSA in rats, Thomas andParrott
(11) noted that antigen was absorbed as native protein, and therefore thought it
likely that they were dealing with low-zone tolerance (13), rather than with
effects oftolerogenic products such as are knownto ariseby"deaggregation" (14,
15) or proteolysis (16) of certain antigens. Incidentally, a water-soluble tolero-
genic extract from erythrocytes has been described (17). In our experiments,
however, the absence of tolerogen in serum collected 24 h after a massive
intragastric dose of SRBC (Tables IV and V) speaks against the paralyzing
material being either intact, deaggregated, or degraded antigen. Rather it
seems that some form ofimmune response must be set up by the body before the
tolerogen can make its appearance in the blood. Both in our case and in the
experiment ofThomas and Parrott (11) there existed a serum antibody response
before the revelation ofthe hyporesponsive state. More significant, though, was
the finding that the tolerogenic factor could be removed from the serum by a
procedure known to eliminate soluble AgAb complexes (exp. 2, Table V).
Immune complexes formed in slight excess ofantigen can be powerful tolero-
gens, possibly because they represent a highly multivalent form ofantigen (18,
19). Schraderand Nossal havespeculated thatcomplexesofappropriate composi-
tion may therefore also be capable of "effector cell blockade." This is precisely
what the data reported here imply.
In our system, only the enteric, not the parenteral, induction of a primary
response appeared to give rise to circulating tolerogenic immune complexes.
Perhaps this was due to the predominantly IgA character of the former re-
sponse, as opposed to the IgM character ofthe parenterally induced response. It
is interestingthat the immune complexes present in thetolerizing immune sera
could be detectedby means ofrheumatoid factor but not by using C1q. Immune
complexes containing IgA as the main or sole antibody should behave inexactly
that way; a point which we have verified with our latex inhibition test using
aggregated monoclonal immunoglobulins of various classes as models.2
Conclusion .
￿
In summary, then, we propose that enteric immunization may
be unusually able to create secondary immunologic hyporesponsiveness because
it favors the formation of IgA antibody whose immune complexes with the
absorbed antigen are, for a reason yet to be discerned, particularly suited to
paralyze B cells.
To a large extent this mucosal type of immune response presumably takes
place in the gut wall itself. To some extent it may also "metastasize" to distant
lymphoid tissues such as the spleen (1). Athird site to beconsidered is the portal
lymphoid tissue ofthe liver. It is in direct continuity with the lamina propria of
the gut and, like the latter, is a preferred siteofIgA production (18). In addition
it is directly exposed to enterically absorbed antigen carried by the mesenteric
venous blood. Ifthe mechanism oftolerization via IgA immune complexes that
wepropose is correct, a novel explanation may then be given to the productionof1518
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ORALLY INDUCED TOLERANCE
systemic hyporesponsiveness by antigengiven orally (10, 19) or injected into the
portal circulation (20, 21), as well as to the suppression of these effects when the
liver is bypassed by a portocaval transposition (19) .
Summary
We have previously reported on the induction, in mice, of a systemic (splenic)
immune response with IgA as the dominant antibody, as a result of a short (4
day) intragastric immunization course with foreign erythrocytes. This response
was followed by a prolonged period of hyporesponsiveness to similarly adminis-
tered antigen. Here it is shown that this hyporesponsiveness is also manifested
towards antigen given intraperitoneally, and that one is therefore dealing with
tolerance, not with failure to absorb antigen from the gut.
In contrast, mice primed parenterally and then challenged intragastrically,
behaved as if never having any previous contact with the antigen, i.e., with a
primary-type splenic response of predominant IgA character. This agrees with
our former conclusion that splenic responses to enterically absorbed antigen
reflect colonization of the spleen by cells sensitized locally in the gut wall, a site
not readily primed by the parenteral route.
Serum from intragastrically immunized mice contained a very active tolero-
gen. In vivo, it was capable of conferring tolerance to nonimmune recipient
mice . In vitro, it paralyzed the activity of antibody-producing cells. Inhibitory
sera had weak antibody activity, restricted to the IgA class, and contained
immune complexes reacting with rheumatoid factor but not with Clq. Elimina-
tion of these complexes by means of insolubilized rheumatoid factor abolished
the tolerogenic effect. In conclusion, the enterically induced tolerogen seems to
consist of immune complexes with IgA as the antibody.
Technical assistance by Miss M. C. Fargier is gratefully acknowledged.
Received for publication 5 August 1975 .
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